Search results for "topic"

Esthesioneuroblastoma presenting with epifora in a young child

1997

Esthesioneuroblastoma (ENB) is an uncommon tumor believed to arise from the olfactory epithelium. 1 This neoplasm has rarely been reported in children, with only 12 cases reported to date among patients younger than 10 years. 2 The usual initial symptom in children, as in older patients, is nasal obstruction or epistaxis 3 ; consequently, the tumor is often first seen by an otorhinolaryngologist. We report a case of ENB in a young child in whom the initial symptom was epiphora; to our knowledge, this initial symptom is previously unreported, and ENB must now be considered in the differential diagnosis of epiphora in childhood. Report of a Case. A white 6-year-old male child was seen on Janu…

The "Tokyo" consensus on propeller flaps

2011

Background: Overthepastfewyears,theuseofpropellerflaps,whichbasetheir blood supply on subcutaneous tissue or isolated perforators, has become in- creasingly popular. Because no consensus has yet been reached on terminology and nomenclature of the propeller flap, different and confusing uses of the term can be found in the literature. Methods: Inthisarticle,theauthorsreporttheconsensusonthedefinitionand classification of propeller flaps reached by the authors that gathered at the First Tokyo Meeting on Perforator and Propeller Flaps in June of 2009. Some peculiar aspects of the surgical technique are discussed. Results: A propeller flap can be defined as an “island flap that reaches the reci…

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentratio…

2015

Background: OMA is an effective treatment option in SAA. However, little data are available on the long-term-efficacy oft the drug. Objective: To determine the long-term efficacy of OMA in respect to clinical parameters and IgE serum levels. Methods: This was a retrospective, open-label, uncontrolled, multi-center observational study according to the definition of non-interventional studies. 22 non-smoking patients (10 m, 12 f; mean age 47,9 yrs) with SAA were enrolled. Pat were treated with OMA up to for 4 years and total serum IgE levels were assessed at initiation of therapy, after 2-6 ms and 3-5 yrs. Data were recorded on standardized CRFs by the treating physician. Results: The average…

Modifications of a nerve integrity monitor useful in skull base surgery.

1993

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

2008

Summary of consensus a. All patients with GO should (Fig. 1):Be referred to specialist centers;Be encouraged to quit smoking;Receive prompt treatment in order to restore andmaintain euthyroidism.b. Patients with sight-threatening GO should be treatedwith i.v. GCs as the first-line treatment; if the responseis poor after 1–2 weeks, they should be submitted tourgent surgical decompression.c. The treatment of choice for moderate-to-severe GO isi.v. GCs (with or without OR) if the orbitopathy isactive;surgery(orbitaldecompression,squintsurgery,and/or eyelid surgery in this order) should beconsidered if the orbitopathy is inactive.d. In patients with mild GO, local measures and anexpectant strate…

Predatory journals: The silent intruder.

2019

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.

2007

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evid…

Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions o…

2007

Limitations of nasal nitric oxide as a screening method of primary ciliary dyskinesia in childhood

2016

Introduction: Nasal nitric oxide (nNO) has been proposed as a screening tool for primary ciliary dyskinesia (PCD). However, there are no reference values by age in consensus guidelines. Objectives: 1) To analyze differences in nNO among a group of patients with PCD and healthy controls. 2) To determine the proportion of pediatric PCD patients with nNO values similar to healthy population. Methods: Determination of nNO by electrochemical system (NIOX Vario®) in patients with DCP (diagnosis confirmed by digital high speed videomicroscopy) and healthy controls (without asthma, rhinitis or atopic dermatitis), aged between 7 and 60 years. Results: 32 patients (17 children, 53.1%) and 32 controls…